Brown Advisory Inc Ascendis Pharma A/S Transaction History

Brown Advisory Inc

$75.5 Billion
Q4 2024

A detailed history of Brown Advisory Inc transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Brown Advisory Inc holds 36,286 shares of ASND stock, worth $5.23 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

36,286

Previous 467,652 92.24%

Holding current value

$5.23 Million

Previous $69.8 Million 92.85%

% of portfolio

0.01%

Previous 0.09%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$122.0 - $146.6 $52.6 Million - $63.2 Million	-431,366 Reduced 92.24%	36,286 $5 Million
Q3 2024 Nov 13, 2024	SELL	$113.0 - $153.43 $1.25 Million - $1.69 Million	-11,024 Reduced 2.3%	467,652 $69.8 Million
Q2 2024 Aug 14, 2024	SELL	$121.07 - $153.67 $24.9 Million - $31.6 Million	-205,396 Reduced 30.03%	478,676 $65.3 Million
Q1 2024 Apr 24, 2024	BUY	$123.45 - $159.4 $22 Million - $28.4 Million	178,125 Added 35.21%	684,072 $103 Million
Q4 2023 Feb 08, 2024	SELL	$86.1 - $127.36 $358,348 - $530,072	-4,162 Reduced 0.82%	505,947 $63.7 Million
Q3 2023 Oct 24, 2023	BUY	$86.5 - $103.97 $1.14 Million - $1.38 Million	13,227 Added 2.66%	510,109 $47.8 Million
Q2 2023 Jul 31, 2023	BUY	$69.96 - $97.84 $2.13 Million - $2.99 Million	30,510 Added 6.54%	496,882 $44.3 Million
Q1 2023 May 08, 2023	BUY	$104.9 - $126.78 $2.74 Million - $3.31 Million	26,080 Added 5.92%	466,372 $50 Million
Q4 2022 Feb 13, 2023	SELL	$99.42 - $131.97 $19.7 Million - $26.1 Million	-197,709 Reduced 30.99%	440,292 $53.8 Million
Q3 2022 Nov 14, 2022	SELL	$84.03 - $110.23 $1.24 Million - $1.62 Million	-14,723 Reduced 2.26%	638,001 $65.9 Million
Q2 2022 Nov 14, 2022	BUY	$78.08 - $117.61 $10.4 Million - $15.7 Million	133,112 Added 25.62%	652,724 $60.7 Million
Q2 2022 Sep 13, 2022	BUY	$78.08 - $117.61 $462,858 - $697,192	5,928 Added 0.94%	634,007 $58.9 Million
Q2 2022 Aug 02, 2022	BUY	$78.08 - $117.61 $9.48 Million - $14.3 Million	121,419 Added 23.96%	628,079 $58.5 Million
Q1 2022 Nov 14, 2022	SELL	$102.18 - $135.75 $11.7 Million - $15.5 Million	-114,395 Reduced 18.04%	519,612 $61 Million
Q1 2022 Sep 13, 2022	BUY	$102.18 - $135.75 $500,068 - $664,360	4,894 Added 0.98%	506,660 $59.5 Million
Q1 2022 May 09, 2022	BUY	$102.18 - $135.75 $2.62 Million - $3.48 Million	25,612 Added 5.38%	501,766 $58.9 Million
Q4 2021 Jan 27, 2022	BUY	$127.1 - $169.66 $6.98 Million - $9.32 Million	54,927 Added 13.04%	476,154 $64.1 Million
Q3 2021 Nov 12, 2021	BUY	$112.67 - $176.92 $993,298 - $1.56 Million	8,816 Added 2.14%	421,227 $67.1 Million
Q2 2021 Jul 29, 2021	BUY	$121.62 - $145.29 $13.4 Million - $16 Million	109,989 Added 36.37%	412,411 $54.3 Million
Q1 2021 May 14, 2021	BUY	$124.92 - $173.33 $31.9 Million - $44.3 Million	255,728 Added 547.67%	302,422 $39 Million
Q4 2020 Feb 12, 2021	BUY	$151.2 - $182.76 $1.25 Million - $1.51 Million	8,253 Added 21.47%	46,694 $7.79 Million
Q3 2020 Nov 16, 2020	BUY	$134.29 - $154.32 $2.01 Million - $2.31 Million	15,001 Added 64.0%	38,441 $5.93 Million
Q2 2020 Aug 14, 2020	BUY	$110.87 - $156.01 $2.6 Million - $3.66 Million	23,440 New	23,440 $3.47 Million
Q2 2019 Aug 12, 2019	SELL	$107.11 - $132.09 $665,688 - $820,939	-6,215 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$62.15 - $129.99 $386,262 - $807,887	6,215 New	6,215 $732,000

Others Institutions Holding ASND

# of Institutions

236

Shares Held

59.6M

Call Options Held

108K

Put Options Held

234K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $8.04B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Brown Advisory Inc, based on Form 13F filings with the SEC.

News

Stay updated on Brown Advisory Inc with notifications on news.

Account

Brown Advisory Inc Ascendis Pharma A/S Transaction History